Test Predicts Benefit of Chemo in ER+, HER2− Breast CancerLast Updated: May 08, 2019. EndoPredict is prognostic for distant recurrence in women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, according to a study published online April 30 in Breast Cancer Research and Treatment.
WEDNESDAY, May 8, 2019 (HealthDay News) -- EndoPredict (EPclin) is prognostic for distant recurrence (DR) in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according to a study published online April 30 in Breast Cancer Research and Treatment.
Ivana Sestak, Ph.D., from Queen Mary University of London, and colleagues examined the performance of EPclin for estimating 10-year DR-free interval rates for 2,630 women receiving five years of endocrine therapy (ET) alone and 1,116 patients receiving ET + chemotherapy (C).
The researchers found that in women who received ET alone and in those who received ET + C, EPclin was highly prognostic for DR (hazard ratios, 2.79 and 2.27, respectively). Significantly smaller increases in 10-year DR rates with the increasing EPclin score were seen for women who received ET + C compared with those receiving ET alone (EPClin = 5; 12 percent for ET + C versus 20 percent for ET alone). A significant positive interaction was seen between EPclin and treatment groups.
"It is clinically important to determine which women with hormone receptor-positive, HER2-negative breast cancer need chemotherapy in addition to standard five-years of hormonal treatment," Sestak said in a statement. "We have shown that EndoPredict has the ability to predict chemotherapy benefit, which will ultimately help clinicians in their decision-making process about adjuvant treatment."
Several authors disclosed financial ties to the biopharmaceutical industry.
|Previous: Percutaneous Ablation in Liver Cancer Tied to Better Outcomes||Next: CDC: Prevalence of Arthritis 22.8 Percent in U.S. Adults in 2017|
Reader comments on this article are listed below. Review our comments policy.